Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$1.42
-4.7%		$1.99
$1.10
▼
$2.68
$631.84M1.072.92 million shs2.68 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-4.49%-9.70%-31.65%-34.93%+7.19%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$1.42
-4.7%		$1.99
$1.10
▼
$2.68
$631.84M1.072.92 million shs2.68 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-4.49%-9.70%-31.65%-34.93%+7.19%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
2.40
Hold$5.70301.41% Upside

Current Analyst Ratings Breakdown

Latest LXRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/21/2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
9/28/2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOverweight$8.00
8/3/2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeStrong-Buy ➝ Hold
7/23/2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 10/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$49.80M12.69N/AN/A$0.30 per share4.73
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$50.34M-$0.15N/AN/AN/A-147.38%-37.53%-24.96%11/5/2026 (Estimated)

Latest LXRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$0.06N/AN/AN/A$4.14 millionN/A
8/6/2026Q2 2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$0.0502-$0.06-$0.0098-$0.07$3.99 million$0.69 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
0.29
13.37
13.29

Institutional Ownership

CompanyInstitutional Ownership
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
74.70%

Insider Ownership

CompanyInsider Ownership
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
14.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
81444.96 million382.66 millionOptionable

Recent News About These Companies

Lexicon Says Sotagliflozin Trial Exceeds Enrollment Goal With 542 Patients
 |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/lexicon-says-sotagliflozin-trial-exceeds-141615103.html
Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy
October 23 at 8:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/23/3387236/0/en/lexicon-pharmaceuticals-provides-update-on-baseline-patient-characteristics-for-pivotal-phase-3-sonata-hcm-study-of-sotagliflozin-in-symptomatic-hypertrophic-cardiomyopathy.html
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Stock Rated "Hold" by Sell-Side Brokerages
October 23 at 4:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-lexicon-pharmaceuticals-inc-nasdaq-lxrx-stock-rated-hold-by-sell-side-brokerages-2026-10-23/
Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease
October 21 at 11:27 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/lexicon-pharmaceuticals-announces-publication-research-123000181.html
Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin's Biological Effects in Cardiovascular Disease
October 21 at 8:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/21/3385524/0/en/lexicon-pharmaceuticals-announces-publication-of-new-research-highlighting-sotagliflozin-s-biological-effects-in-cardiovascular-disease.html
Consensus target rises to USD 4.64 for Lexicon Pharmaceuticals stock
October 16, 2026  |  ad-hoc-news.deA
Cantor sets USD 8.00 target for Lexicon Pharmaceuticals stock
October 13, 2026  |  ad-hoc-news.deA
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Falls 5.2% - What's Next?
October 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-lexicon-pharmaceuticals-nasdaq-lxrx-stock-falls-52-whats-next-2026-10-05/
Lexicon Pharmaceuticals consensus price target increased by 17.91% to $4.64
October 2, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/lexicon-pharmaceuticals-consensus-price-target-increased-by-17-91-to-4-64/ar-AA2dnhU0
Lexicon Pharmaceuticals (LXRX) Stock Fair Value Rises After SONATA HCM Trial Progress
October 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/lexicon-pharmaceuticals-lxrx-stock-fair-051033494.html
Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More
September 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4951120-lexicon-pharmaceuticals-upgrading-on-sotagliflozin-hcm-data-q1-27-and-more?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
Lexicon Pharmaceuticals bondit après une initiation favorable de Cantor Fitzgerald
September 29, 2026  |  fr.finance.yahoo.comhttps://fr.finance.yahoo.com/actualites/lexicon-pharmaceuticals-bondit-apr%C3%A8s-initiation-161023428.html
Lexicon a new overweight at Cantor on optimism for Inpefa in cardiomyopathy
September 28, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4647695-lexicon-new-overweight-cantor-optimism-inpefa-cardiomyopathy
Aktien von Lexicon Pharmaceuticals steigen nach Aufnahme der Beobachtung durch Cantor Fitzgerald mit Overweight-Einstufung
September 28, 2026  |  de.marketscreener.comD
Lexicon Pharmaceuticals Shares Rise After Cantor Fitzgerald Initiates With Overweight Rating
September 28, 2026  |  marketscreener.comM
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today
September 28, 2026  |  fool.comhttps://www.fool.com/investing/2026/09/28/why-lexicon-pharmaceuticals-stock-popped-by-almost/?source=marketbeat&utm_source=marketbeat&utm_medium=feed&utm_campaign=article&referring_guid=16b9b26b-c521-4187-940b-0060e57bf295
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today
September 28, 2026  |  fool.comhttps://www.fool.com/investing/2026/09/28/why-lexicon-pharmaceuticals-stock-popped-by-almost/
Lexicon Pharmaceuticals stijgt fors nu Cantor Fitzgerald onbelemmerde weg ziet bij HCM
September 28, 2026  |  nl.investing.comhttps://nl.investing.com/news/stock-market-news/lexicon-pharmaceuticals-stijgt-fors-nu-cantor-fitzgerald-onbelemmerde-weg-ziet-bij-hcm-925414
Saham Lexicon Pharmaceuticals melonjak usai Cantor Fitzgerald beri prospek cerah di HCM
September 28, 2026  |  id.investing.comhttps://id.investing.com/news/stock-market-news/saham-lexicon-pharmaceuticals-melonjak-usai-cantor-fitzgerald-beri-prospek-cerah-di-hcm-3081534
Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM
September 28, 2026  |  ca.finance.yahoo.comhttps://ca.finance.yahoo.com/news/lexicon-pharmaceuticals-surges-cantor-fitzgerald-161210738.html
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap Up - What's Next?
September 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-lexicon-pharmaceuticals-nasdaq-lxrx-shares-gap-up-whats-next-2026-09-28/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Lexicon Pharmaceuticals stock logo

Lexicon Pharmaceuticals NASDAQ:LXRX

$1.42 -0.07 (-4.70%)
Closing price 04:00 PM Eastern
Extended Trading
$1.42 +0.01 (+0.35%)
As of 06:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas